NeuroVive announces departure of CEO and appointment of Jan Nilsson as interim CEO

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company,
announces a change in leadership of the company.  Effective today, Mikael
Brönnegård will no longer serve as Chief Executive Officer. The Board is pleased
to announce that NeuroVive’s COO Jan Nilsson, who has extensive experience at
senior levels within international pharmaceutical companies, will take over as
interim CEO.
The recruitment process to find a successor has begun and the company’s COO Jan
Nilsson will head up the company in the role of interim CEO in the period until
a new CEO is appointed by the Board of Directors.

“We would like to thank Mikael Brönnegård for his service to the company and
wish him success in his future endeavors.  We believe that the time is right for
a change in the leadership of the company’s management team.  The NeuroVive
board is confident that Jan Nilsson has the experience required to lead the
company until a new CEO has been recruited,” commented Gregory Batcheller,
NeuroVive’s Chairman.

About NeuroVive
NeuroVive Pharmaceutical AB (publ) is a mitochondrial medicine company committed
to the discovery and development of therapeutic applications for mitochondrial
medicine in areas of significant unmet clinical need. NeuroVive’s business
strategy focuses on maximising value from its projects through strategic
partnerships and outlicensing.

NeuroVive’s portfolio, containing three cyclophilin D candidates in clinical and
preclinical development, is fuelled by three additional drug discovery platforms
in neurology, mitochondrial disorders and organ protection. NeuroVive’s product
CicloMulsion® is being evaluated in an ongoing Phase II study, CiPRICS, in acute
kidney injury during major surgery. The NeuroSTAT® product is currently being
evaluated in a Phase II study in traumatic brain injury.  NeuroVive’s shares are
listed on NASDAQ OMX, Stockholm, Sweden.

For investor relations and media questions, please contact:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (46)275 62 21 or ir@neurovive.se

It is also possible to arrange an interview with NeuroVive’s Chairman Gregory
Batcheller at the above contacts.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.se, www.neurovive.se

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under The Swedish Securities Market Act. The information was
submitted for publication on 1 September 2015, at 13.50 CET.
NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The
company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol
NVP. The share is also traded on the OTC market in the US. NeuroVive
Pharmaceutical (OTC: NEVPF) trades on the OTC Pink Market. Investors can find
Real-Time quotes and market information for the company
at www.otcmarkets.com/stock/NEVPF/quote (http://htt://www.otcmarkets.com/stock/N
E 
VPF/quot)